Diagnostic Name (Manufacturer)	Indication	Sample_type	Drug Trade Name (Generic) NDA / BLA	NDA Number	Biomarker(s)	Biomarker(s) (Details)	PMA / 510(k) / 513(f)(2) / HDE (Approval / Clearance / Grant Date)	Date	OncoTree	OncoKB Drug name	OncoKB Gene	OncoKB Biomarker
Abbott RealTime IDH1 (Abbott Molecular, Inc.)	Acute Myeloid Leukemia	Peripheral Blood or Bone Marrow	Tibsovo (ivosidenib)	NDA 211192	IDH1	R132 mutations (R132C, R132H, R132G, R132S, and R132L)	P170041	(07/20/2018)	Acute Myeloid Leukemia	Ivosidenib	IDH1	R132C, R132G, R132H, R132L, R132S
Abbott RealTime IDH1 (Abbott Molecular, Inc.)	Acute Myeloid Leukemia	Peripheral Blood or Bone Marrow	Rezlidhia (olutasidenib)	NDA 215814	IDH1	R132 mutations (R132C, R132H, R132G, R132S, and R132L)	P170041/S006	(12/01/2022)	Acute Myeloid Leukemia	Olutasidenib	IDH1	R132C, R132G, R132H, R132L, R132S
Abbott RealTime IDH2 (Abbott Molecular, Inc.)	Acute Myeloid Leukemia	Peripheral Blood or Bone Marrow	Idhifa (enasidenib)	NDA 209606	IDH2	R140Q, R140L, R140G, R140W, R172K, R172M, R172G, R172S, and R172W	P170005	(08/01/2017)	Acute Myeloid Leukemia	Enasidenib	IDH2	R140G, R140L, R140Q, R140W, R172G, R172K, R172M, R172S, R172W
Agilent Resolution ctDx FIRST assay (Resolution Bioscience, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Plasma	Krazati (adagrasib)	NDA 216340	KRAS	KRAS G12C	P210040	(12/12/2022)	Non-Small Cell Lung Cancer	Adagrasib	KRAS	G12C
Bond Oracle HER2 IHC System (Leica Biosystems)	Breast Cancer	Tissue	Herceptin (trastuzumab)	BLA 103792	ERBB2 (HER2)	HER-2 protein overexpression	P090015	(04/18/2012)	NA	Not in OncoKB	Not in OncoKB	Not in OncoKB
BRACAnalysis CDx (Myriad Genetic Laboratories, Inc.)	Ovarian Cancer	Whole Blood	Lynparza (olaparib)	NDA 208558	BRCA1 and BRCA2	Mutations	P140020	(12/19/2014)	Ovarian Cancer, Ovary/Fallopian Tube, Peritoneal Serous Carcinoma	Olaparib, Olaparib + Bevacizumab	BRCA1 and BRCA2	Oncogenic Mutations
BRACAnalysis CDx (Myriad Genetic Laboratories, Inc.)	Breast Cancer	Whole Blood	Lynparza (olaparib)	NDA 208558	BRCA1 and BRCA2	Mutations	P140020/S012	(01/12/2018)	NA	Not in OncoKB	Not in OncoKB	Not in OncoKB
BRACAnalysis CDx (Myriad Genetic Laboratories, Inc.)	Breast Cancer	Whole Blood	Talzenna (talazoparib)	NDA 211651	BRCA1 and BRCA2	Mutations	P140020/S015	(10/16/2018)	NA	Not in OncoKB	Not in OncoKB	Not in OncoKB
BRACAnalysis CDx (Myriad Genetic Laboratories, Inc.)	Ovarian Cancer	Whole Blood	Rubraca (rucaparib)	NDA 209115	BRCA1 and BRCA2	Mutations	P140020/S016	(10/16/2018)	Ovarian Cancer, Ovary/Fallopian Tube, Peritoneal Serous Carcinoma	Rucaparib	BRCA1 and BRCA2	Oncogenic Mutations
BRACAnalysis CDx (Myriad Genetic Laboratories, Inc.)	Pancreatic Cancer	Whole Blood	Lynparza (olaparib)	NDA 208558	BRCA1 and BRCA2	Mutations	P140020/S019	(12/27/2019)	NA	Not in OncoKB	Not in OncoKB	Not in OncoKB
BRACAnalysis CDx (Myriad Genetic Laboratories, Inc.)	Metastatic Castrate Resistant Prostate Cancer (mCRPC)	Whole Blood	Lynparza (olaparib)	NDA 208558	BRCA1 and BRCA2	Mutations	P140020/S020	(05/19/2020)	Prostate Cancer, NOS, Prostate Cancer	Olaparib	BRCA1 and BRCA2	Oncogenic Mutations
cobas 4800 BRAF V600 Mutation Test (Roche Molecular Systems, Inc.)	Melanoma	Tissue	Zelboraf (vemurafenib)	NDA 202429	BRAF	V600E	P110020	(08/17/2011)	Melanoma	Vemurafenib	BRAF	V600E
cobas 4800 BRAF V600 Mutation Test (Roche Molecular Systems, Inc.)	Melanoma	Tissue	Cotellic (cobimetinib) in combination with Zelboraf (vemurafenib)	NDA 206192 + NDA 202429	BRAF	V600E or V600K	P110020/S016	(11/07/2016)	Melanoma	Vemurafenib + Cobimetinib	BRAF	V600E, V600K
cobas EGFR Mutation Test v1 (Roche Molecular Systems, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Tarceva (erlotinib)	NDA 021743	EGFR (HER1)	Exon 19 deletion or exon 21 L858R substitution mutation	P120019	(07/15/2013)	Non-Small Cell Lung Cancer	Erlotinib	EGFR	Exon 19 in-frame deletions, L858R
cobas EGFR Mutation Test v2 (Roche Molecular Systems, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Tagrisso (osimertinib)	NDA 208065	EGFR (HER1)	T790M	P120019/S007	(11/13/2015)	Non-Small Cell Lung Cancer	Osimertinib	EGFR	T790M
cobas EGFR Mutation Test v2 (Roche Molecular Systems, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Tagrisso (osimertinib)	NDA 208065	EGFR (HER1)	Exon 19 deletion or exon 21 L858R substitution mutation	P120019/S016	(04/18/2018)	Non-Small Cell Lung Cancer	Osimertinib	EGFR	Exon 19 in-frame deletions, L858R
cobas EGFR Mutation Test v2 (Roche Molecular Systems, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Plasma	Tagrisso (osimertinib)	NDA 208065	EGFR (HER1)	Exon 19 deletion or exon 21 L858R substitution mutation	P120019/S018	(04/18/2018)	Non-Small Cell Lung Cancer	Osimertinib	EGFR	Exon 19 in-frame deletions, L858R
cobas EGFR Mutation Test v2 (Roche Molecular Systems, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue or Plasma	Iressa (gefitinib)	NDA 206995	EGFR (HER1)	Exon 19 deletion or exon 21 L858R substitution mutation	P120019/S019	(08/22/0218)	Non-Small Cell Lung Cancer	Gefitinib	EGFR	Exon 19 in-frame deletions, L858R
cobas EGFR Mutation Test v2 (Roche Molecular Systems, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue or Plasma	Iressa (gefitinib)	NDA 206995	EGFR (HER1)	Exon 19 deletion or exon 21 L858R substitution mutation	P120019/S031	(10/27/2020)	Non-Small Cell Lung Cancer	Gefitinib	EGFR	Exon 19 in-frame deletions, L858R
cobas EGFR Mutation Test v2 (Roche Molecular Systems, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue or Plasma	Tarceva (erlotinib)	NDA 021743	EGFR (HER1)	Exon 19 deletion or exon 21 L858R substitution mutation	P120019/S031	(10/27/2020)	Non-Small Cell Lung Cancer	Erlotinib	EGFR	Exon 19 in-frame deletions, L858R
cobas EGFR Mutation Test v2 (Roche Molecular Systems, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue or Plasma	Gilotrif (afatinib)	NDA 201292	EGFR (HER1)	Exon 19 deletion or exon 21 L858R substitution mutation	P120019/S031	(10/27/2020)	Non-Small Cell Lung Cancer	Afatinib	EGFR	Exon 19 in-frame deletions, L858R
cobas EGFR Mutation Test v2 (Roche Molecular Systems, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue or Plasma	Tagrisso (osimertinib)	NDA 208065	EGFR (HER1)	Exon 19 deletion or exon 21 L858R substitution mutation	P120019/S031	(10/27/2020)	Non-Small Cell Lung Cancer	Osimertinib	EGFR	Exon 19 in-frame deletions, L858R
cobas EGFR Mutation Test v2 (Roche Molecular Systems, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Plasma	Tagrisso (osimertinib)	NDA 208065	EGFR (HER1)	T790M	P150044	(09/28/2016)	Non-Small Cell Lung Cancer	Osimertinib	EGFR	T790M
cobas EGFR Mutation Test v2 (Roche Molecular Systems, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Plasma	Tarceva (erlotinib)	NDA 021743	EGFR (HER1)	Exon 19 deletion or exon 21 L858R substitution mutation	P150047	(06/01/2016)	Non-Small Cell Lung Cancer	Erlotinib	EGFR	Exon 19 in-frame deletions, L858R
cobas EZH2 Mutation Test (Roche Molecular Systems, Inc.)	Follicular Lymphoma Tumor	Tissue	Tazverik (tazemetostat)	NDA 213400	EZH2	Y646N, Y646F or Y646X (Y646H, Y646S, or Y646C), A682G, and A692V of the EZH2 gene	P200014	(06/18/2020)	Follicular Lymphoma	Tazemetostat	EZH2	A682G, A692V, Y646C, Y646F, Y646H, Y646N, Y646S
cobas KRAS Mutation Test (Roche Molecular Systems, Inc.)	Colorectal Cancer	Tissue	Erbitux (cetuximab)	BLA 125084	KRAS	Mutations in codons 12 and 13 of KRAS gene	P140023	(05/07/2015)	NA	Not in OncoKB	Not in OncoKB	Not in OncoKB
cobas KRAS Mutation Test (Roche Molecular Systems, Inc.)	Colorectal Cancer	Tissue	Vectibix (panitumumab)	BLA 125147	KRAS	Mutations in codons 12 and 13 of KRAS gene	P140023	(05/07/2015)	NA	Not in OncoKB	Not in OncoKB	Not in OncoKB
Dako c-KIT pharmDx (Dako North America, Inc.)	Gastrointestinal Stromal Tumors	Tissue	Gleevec (imatinib mesylate)	NDA 021588	C-Kit	C-Kit protein expression in CD117 antigen-expressing cells	P040011	(06/27/2005)	NA	Not in OncoKB	Not in OncoKB	Not in OncoKB
Dako EGFR pharmDx Kit (Dako North America, Inc.)	Colorectal Cancer	Tissue	Erbitux (cetuximab)	BLA 125084	EGFR (HER1)	EGFR (HER1) protein expression	P030044	(02/12/2004)	NA	Not in OncoKB	Not in OncoKB	Not in OncoKB
Dako EGFR pharmDx Kit (Dako North America, Inc.)	Colorectal Cancer	Tissue	Vectibix (panitumumab)	BLA 125147	EGFR (HER1)	EGFR (HER1) protein expression	P030044/S002	(09/27/2006)	NA	Not in OncoKB	Not in OncoKB	Not in OncoKB
FoundationFocus CDxBRCA Assay (Foundation Medicine, Inc.)	Ovarian Cancer	Tissue	Rubraca (rucaparib)	NDA 209115	BRCA1 and BRCA2	BRCA1 and BRCA2 alterations	P160018	(12/19/2016)	Ovarian Cancer, Ovary/Fallopian Tube, Peritoneal Serous Carcinoma	Rucaparib	BRCA1 and BRCA2	Oncogenic Mutations
FoundationOne CDx (Foundation Medicine, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Gilotrif (afatinib)	NDA 201292	EGFR (HER1)	Exon 19 deletion or exon 21 L858R substitution mutation	P170019	(11/30/2017)	Non-Small Cell Lung Cancer	Afatinib	EGFR	Exon 19 in-frame deletions, L858R
FoundationOne CDx (Foundation Medicine, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Iressa (gefitinib)	NDA 206995	EGFR (HER1)	Exon 19 deletion or exon 21 L858R substitution mutation	P170019	(11/30/2017)	Non-Small Cell Lung Cancer	Gefitinib	EGFR	Exon 19 in-frame deletions, L858R
FoundationOne CDx (Foundation Medicine, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Tarceva (erlotinib)	NDA 021743	EGFR (HER1)	Exon 19 deletion or exon 21 L858R substitution mutation	P170019	(11/30/2017)	Non-Small Cell Lung Cancer	Erlotinib	EGFR	Exon 19 in-frame deletions, L858R
FoundationOne CDx (Foundation Medicine, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Tagrisso (osimertinib)	NDA 208065	EGFR (HER1)	T790M	P170019	(11/30/2017)	Non-Small Cell Lung Cancer	Osimertinib	EGFR	T790M
FoundationOne CDx (Foundation Medicine, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Alecensa (alectinib)	NDA 208434	ALK	ALK rearrangements	P170019	(11/30/2017)	Non-Small Cell Lung Cancer	Alectinib	ALK	Fusions
FoundationOne CDx (Foundation Medicine, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Xalkori (crizotinib)	NDA 202570	ALK	ALK rearrangements	P170019	(11/30/2017)	Non-Small Cell Lung Cancer	Crizotinib	ALK	Fusions
FoundationOne CDx (Foundation Medicine, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Zykadia (ceritinib)	NDA 211225	ALK	ALK rearrangements	P170019	(11/30/2017)	Non-Small Cell Lung Cancer	Ceritinib	ALK	Fusions
FoundationOne CDx (Foundation Medicine, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Tafinlar (dabrafenib) in combination with Mekinist (trametinib)	NDA 202806 + NDA 204114	BRAF	V600E	P170019	(11/30/2017)	Non-Small Cell Lung Cancer	Dabrafenib + Trametinib	BRAF	V600E
FoundationOne CDx (Foundation Medicine, Inc.)	Breast Cancer	Tissue	Herceptin (trastuzumab)	BLA 103792	ERBB2 (HER2)	ERBB2 (HER2) amplification	P170019	(11/30/2017)	Breast Cancer	trastuzumab	ERBB2 (HER2)	
FoundationOne CDx (Foundation Medicine, Inc.)	Breast Cancer	Tissue	Perjeta (pertuzumab)	BLA 125409	ERBB2 (HER2)	ERBB2 (HER2) amplification	P170019	(11/30/2017)	Breast Cancer	pertuzumab	ERBB2 (HER2)	
FoundationOne CDx (Foundation Medicine, Inc.)	Breast Cancer	Tissue	Kadcyla (ado-trastuzumab emtansine)	BLA 125427	ERBB2 (HER2)	ERBB2 (HER2) amplification	P170019	(11/30/2017)	Breast Cancer	Ado-Trastuzumab Emtansine	ERBB2	Amplification
FoundationOne CDx (Foundation Medicine, Inc.)	Colorectal Cancer	Tissue	Erbitux (cetuximab)	BLA 125084	KRAS	KRAS wild-type (absence of mutations in codons 12 and 13)	P170019	(11/30/2017)	Colorectal Cancer	Cetuximab, Cetuximab + Chemotherapy	KRAS	Wildtype
FoundationOne CDx (Foundation Medicine, Inc.)	Colorectal Cancer	Tissue	Vectibix (panitumumab)	BLA 125147	KRAS and NRAS	KRAS wild-type (absence of mutations in exons 2, 3, and 4) and NRAS wild type (absence of mutations in exons 2, 3, and 4)	P170019	(11/30/2017)	Colorectal Cancer	Panitumumab, Panitumumab + Chemotherapy	KRAS,NRAS	Wildtype
FoundationOne CDx (Foundation Medicine, Inc.)	Ovarian Cancer	Tissue	Rubraca (rucaparib)	NDA 209115	BRCA1 and BRCA2	BRCA1 and BRCA2 alterations	P170019	(11/30/2017)	Ovarian Cancer, Ovary/Fallopian Tube, Peritoneal Serous Carcinoma	Rucaparib	BRCA1 and BRCA2	Oncogenic Mutations
FoundationOne CDx (Foundation Medicine, Inc.)	Melanoma	Tissue	Mekinist (trametinib)	NDA 204114	BRAF	V600E and V600K	P170019	(11/30/2017)	Melanoma	Trametinib	BRAF	V600E, V600K
FoundationOne CDx (Foundation Medicine, Inc.)	Ovarian Cancer	Tissue	Lynparza (olaparib)	NDA 208558	BRCA1 and BRCA2	BRCA1 and BRCA2 alterations	P170019/S004	(07/01/2019)	Ovarian Cancer, Ovary/Fallopian Tube, Peritoneal Serous Carcinoma	Rucaparib	BRCA1 and BRCA2	Oncogenic Mutations
FoundationOne CDx (Foundation Medicine, Inc.)	Breast Cancer	Tissue	Piqray (alpelisib)	NDA 212526	PIK3CA	C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047Y	P170019/S006	(12/03/2019)	Breast Cancer	Alpelisib + Fulvestrant	PIK3CA	C420R, E542K, E545A, E545D, E545G, E545K, H1047L, H1047R, H1047Y, Q546E, Q546R
FoundationOne CDx (Foundation Medicine, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Tagrisso (osimertinib)	NDA 208065	EGFR (HER1)	Exon 19 deletion or exon 21 L858R substitution mutation	P170019/S008	(07/01/2019)	Non-Small Cell Lung Cancer	Osimertinib	EGFR	Exon 19 in-frame deletions, L858R
FoundationOne CDx (Foundation Medicine, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Tabrecta (capmatinib)	NDA 213591	MET	MET single nucleotide variants and indels that lead to MET exon 14 skipping	P170019/S011	(05/06/2020)	Non-Small Cell Lung Cancer	Capmatinib	MET	D1010, Exon 14 Deletion, Exon 14 in-frame deletions, Exon 14 splice mutations
FoundationOne CDx (Foundation Medicine, Inc.)	Cholangiocarcinoma	Tissue	Pemazyre (pemigatinib)	NDA 213736	FGFR2	FGFR2 fusions and select rearrangements	P170019/S013	(04/17/2020)	Cholangiocarcinoma	Pemigatinib	FGFR2	Fusions
FoundationOne CDx (Foundation Medicine, Inc.)	Metastatic Castrate Resistant Prostate Cancer (mCRPC)	Tissue	Lynparza (olaparib)	NDA 208558	Homologous recombination repair (HRR) genes	BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D and RAD54L alterations	P170019/S015	(05/19/2020)	Prostate Cancer, NOS, Prostate Cancer	Olaparib	BRCA1, BRCA2, ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, PALB2, RAD51B, RAD51C, RAD51D and RAD54L	Oncogenic Mutations
FoundationOne CDx (Foundation Medicine, Inc.)	Solid Tumors	Tissue	Keytruda (pembrolizumab)	BLA 125514	TMB	TMB ≥ 10 mutations per megabase	P170019/S016	(06/16/2020)	All Solid Tumors	Pembrolizumab	Other Biomarkers	Tumor Mutational Burden-High
FoundationOne CDx (Foundation Medicine, Inc.)	Solid Tumors	Tissue	Vitrakvi (larotrectinib)	NDA 210861	NTRK1, NTRK2 and NTRK3	NTRK1, NTRK2 and NTRK3 fusions	P170019/S017	(10/23/2020)	All Solid Tumors	Larotrectinib	NTRK1, NTRK2, NTRK3	Fusions
FoundationOne CDx (Foundation Medicine, Inc.)	Cholangiocarcinoma	Tissue	Truseltiq (infigratinib)	NDA 214622	FGFR2	FGFR2 fusions/rearrangements	P170019/S021	(05/28/2021)	NA	Not in OncoKB	Not in OncoKB	Not in OncoKB
FoundationOne CDx (Foundation Medicine, Inc.)	Solid Tumors	Tissue	Keytruda (pembrolizumab)	BLA 125514	MSI-High	Microsatellite instability-High (MSI-H)	P170019/S029	(02/18/2022)	All Solid Tumors	Pembrolizumab	Other Biomarkers	Microsatellite Instability-High
FoundationOne CDx (Foundation Medicine, Inc.)	Melanoma	Tissue	Tecentriq (atezolizumab) in combination with Cotellic (cobimetinib) and Zelboraf (vemurafenib)	BLA 761034 + NDA 206192 + NDA 202429	BRAF	BRAF V600 mutations	P170019/S030	(01/19/2022)	Melanoma	Vemurafenib + Atezolizumab + Cobimetinib	BRAF	V600
FoundationOne CDx (Foundation Medicine, Inc.)	Solid Tumors	Tissue	Rozlytrek (entrectinib)	NDA 212725	NTRK1, NTRK2 and NTRK3	NTRK1, NTRK2 and NTRK3 fusions	P170019/S014	(06/07/2022)	All Solid Tumors	Entrectinib	NTRK1, NTRK2, NTRK3	Fusions
FoundationOne CDx (Foundation Medicine, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Rozlytrek (entrectinib)	NDA 212725	ROS1	ROS1 fusions	P170019/S014	(06/07/2022)	Non-Small Cell Lung Cancer	Entrectinib	ROS1	Fusions
FoundationOne Liquid CDx (Foundation Medicine, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Plasma	Exkivity (mobocertinib)	NDA 215310	EGFR (HER1)	Exon 20 insertion mutations	P190032/S005	(05/03/2023)	Non-Small Cell Lung Cancer	Mobocertinib	EGFR	Exon 20 in-frame insertions
FoundationOne Liquid CDx (Foundation Medicine, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Plasma	Iressa (gefitinib)	NDA 206995	EGFR (HER1)	Exon 19 deletion or exon 21 L858R substitution mutation	P190032 and P190032/S008	(08/26/2020) and (12/19/2022)	Non-Small Cell Lung Cancer	Gefitinib	EGFR	Exon 19 in-frame deletions, L858R
FoundationOne Liquid CDx (Foundation Medicine, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Plasma	Tagrisso (osimertinib)	NDA 208065	EGFR (HER1)	Exon 19 deletion or exon 21 L858R substitution mutation	P190032 and P190032/S008	(08/26/2020) and (12/19/2022)	Non-Small Cell Lung Cancer	Osimertinib	EGFR	Exon 19 in-frame deletions, L858R
FoundationOne Liquid CDx (Foundation Medicine, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Plasma	Tarceva (erlotinib)	NDA 021743	EGFR (HER1)	Exon 19 deletion or exon 21 L858R substitution mutation	P190032 and P190032/S008	(08/26/2020) and (12/19/2022)	Non-Small Cell Lung Cancer	Erlotinib	EGFR	Exon 19 in-frame deletions, L858R
FoundationOne Liquid CDx (Foundation Medicine, Inc.)	Metastatic Castrate Resistant Prostate Cancer (mCRPC)	Plasma	Rubraca (rucaparib)	NDA 209115	BRCA1 and BRCA2	BRCA1 and BRCA2 alterations	P190032	(08/26/2020)	Metastatic Castrate Resistant Prostate Cancer (mCRPC)	rucaparib	BRCA1 and BRCA2	
FoundationOne Liquid CDx (Foundation Medicine, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Plasma	Tabrecta (capmatinib)	NDA 213591	MET	MET single nucleotide variants and indels that lead to MET exon 14 skipping	P190032/S001	(07/15/2021)	Non-Small Cell Lung Cancer	Capmatinib	MET	D1010, Exon 14 Deletion, Exon 14 in-frame deletions, Exon 14 splice mutations
FoundationOne Liquid CDx (Foundation Medicine, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Plasma	Rozlytrek (entrectinib)	NDA 212725	ROS1	ROS1 fusions	P190032/S004	(12/22/2022)	Non-Small Cell Lung Cancer	Entrectinib	ROS1	Fusions
FoundationOne Liquid CDx (Foundation Medicine, Inc.)	Solid Tumors	Plasma	Rozlytrek (entrectinib)	NDA 212725	NTRK1, NTRK2, and NTRK3 fusions	NTRK1/2/3 fusions	P190032/S004	(12/22/2022)	All Solid Tumors	Entrectinib	NTRK1, NTRK2, NTRK3	Fusions
FoundationOne Liquid CDx (Foundation Medicine, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Plasma	Alecensa (alectinib)	NDA 208434	ALK	ALK rearrangements	P200006	(10/26/2020)	Non-Small Cell Lung Cancer	Alectinib	ALK	Fusions
FoundationOne Liquid CDx (Foundation Medicine, Inc.)	Ovarian Cancer	Plasma	Rubraca (rucaparib)	NDA 209115	BRCA1 and BRCA2	BRCA1 and BRCA2 alterations	P200006	(10/26/2020)	Ovarian Cancer	rucaparib	BRCA1 and BRCA2	
FoundationOne Liquid CDx (Foundation Medicine, Inc.)	Breast Cancer	Plasma	Piqray (alpelisib)	NDA 212526	PIK3CA	C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047Y	P200006	(10/26/2020)	Breast Cancer	Alpelisib + Fulvestrant	PIK3CA	C420R, E542K, E545A, E545D, E545G, E545K, H1047L, H1047R, H1047Y, Q546E, Q546R
FoundationOne Liquid CDx (Foundation Medicine, Inc.)	Metastatic Castrate Resistant Prostate Cancer (mCRPC)	Plasma	Lynparza (olaparib)	NDA 208558	BRCA1, BRCA2 and ATM	BRCA1, BRCA2, and ATM alterations	P200006	(10/26/2020)	Metastatic Castrate Resistant Prostate Cancer (mCRPC)	Prostate Cancer, NOS, Prostate Cancer	Olaparib	BRCA1, BRCA2, ATM
Guardant360 CDx (Guardant Health, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Plasma	Tagrisso (osimertinib)	NDA 208065	EGFR (HER1)	EGFR exon 19 deletions, EGFR exon 21 L858R, and T790M	P200010	(08/07/2020)	Non-Small Cell Lung Cancer	Osimertinib	EGFR	Exon 19 in-frame deletions, L858R
Guardant360 CDx (Guardant Health, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Plasma	Rybrevant (amivantamb)	BLA 761210	EGFR (HER1)	EGFR exon 20 insertions	P200010/S001	(05/21/2021)	Non-Small Cell Lung Cancer	Amivantamab	EGFR	Exon 20 in-frame insertions
Guardant360 CDx (Guardant Health, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Plasma	Lumakras (sotorasib)	NDA 214665	KRAS	G12C	P200010/S002	(05/28/2021)	Non-Small Cell Lung Cancer	Sotorasib	KRAS	G12C
Guardant360 CDx (Guardant Health, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Plasma	ENHERTU (fam-trastuzumab deruxtecan-nxki)	BLA 761139	ERBB2	ERBB2 Activating Mutations (SNVs And Exon 20 Insertions)	P200010/S008	(08/11/2022)	Non-Small Cell Lung Cancer	Trastuzumab Deruxtecan	ERBB2	Oncogenic Mutations
Guardant360 CDx (Guardant Health, Inc.)	Breast Cancer	Plasma	Orserdu (elacestrant)	NDA 217639	ESR1	ESR1 missense mutations between codons 310 and 547	P200010/S010	(01/27/2023)	Breast Cancer	Elacestrant	ESR1	D538, E380, L469V, L536, S463P, Y537
HER2 CISH pharmDx Kit (Dako Denmark A/S)	Breast Cancer	Tissue	Herceptin (trastuzumab)	BLA 103792	ERBB2 (HER2)	HER-2/neu (ERBB2) gene amplification	P100024	(11/30/2011)	Breast Cancer	trastuzumab	ERBB2 (HER2)	
HER2 FISH pharmDx Kit (Dako Denmark A/S)	Breast Cancer	Tissue	Herceptin (trastuzumab)	BLA 103792	ERBB2 (HER2)	HER-2/neu (ERBB2) gene amplification	P040005	(05/03/2005)	Breast Cancer	trastuzumab	ERBB2 (HER2)	
HER2 FISH pharmDx Kit (Dako Denmark A/S)	Gastric and Gastroesophageal Cancer	Tissue	Herceptin (trastuzumab)	BLA 103792	ERBB2 (HER2)	HER-2/neu (ERBB2) gene amplification	P040005/S005	(10/20/2010)	Gastric and Gastroesophageal Cancer	trastuzumab	ERBB2 (HER2)	
HER2 FISH pharmDx Kit (Dako Denmark A/S)	Breast Cancer	Tissue	Perjeta (pertuzumab)	BLA 125409	ERBB2 (HER2)	HER-2/neu (ERBB2) gene amplification	P040005/S006	(06/08/2012)	Breast Cancer	pertuzumab	ERBB2 (HER2)	
HER2 FISH pharmDx Kit (Dako Denmark A/S)	Breast Cancer	Tissue	Kadcyla (ado-trastuzumab emtansine)	BLA 125427	ERBB2 (HER2)	HER-2/neu (ERBB2) gene amplification	P040005/S009	(02/22/2013)	Breast Cancer	ado-trastuzumab emtansine	ERBB2 (HER2)	
HercepTest (Dako Denmark A/S)	Breast Cancer	Tissue	Herceptin (trastuzumab)	BLA 103792	ERBB2 (HER2)	HER-2 protein overexpression	P980018	(09/25/1998)	Breast Cancer	trastuzumab	ERBB2 (HER2)	
HercepTest (Dako Denmark A/S)	Gastric and Gastroesophageal Cancer	Tissue	Herceptin (trastuzumab)	BLA 103792	ERBB2 (HER2)	HER-2 protein overexpression	P980018/S010	(10/20/2010)	Gastric and Gastroesophageal Cancer	trastuzumab	ERBB2 (HER2)	
HercepTest (Dako Denmark A/S)	Breast Cancer	Tissue	Perjeta (pertuzumab)	BLA 125409	ERBB2 (HER2)	HER-2 protein overexpression	P980018/S015	(06/08/2012)	Breast Cancer	pertuzumab	ERBB2 (HER2)	
HercepTest (Dako Denmark A/S)	Breast Cancer	Tissue	Kadcyla (ado-trastuzumab emtansine)	BLA 125427	ERBB2 (HER2)	HER-2 protein overexpression	P980018/S016	(02/22/2013)	Breast Cancer	ado-trastuzumab emtansine	ERBB2 (HER2)	
INFORM HER-2/neu (Ventana Medical Systems, Inc.)	Breast Cancer	Tissue	Herceptin (trastuzumab)	BLA 103792	ERBB2 (HER2)	HER-2/neu (ERBB2) gene amplification	P940004	(12/30/1997)	Breast Cancer	trastuzumab	ERBB2 (HER2)	
INFORM HER2 Dual ISH DNA Probe Cocktail (Ventana Medical Systems, Inc.)	Breast Cancer	Tissue	Herceptin (trastuzumab)	BLA 103792	ERBB2 (HER2)	HER-2/neu (ERBB2) gene amplification	P100027	(06/14/2011)	Breast Cancer	trastuzumab	ERBB2 (HER2)	
INFORM HER2 Dual ISH DNA Probe Cocktail (Ventana Medical Systems, Inc.)	Breast Cancer	Tissue	Kadcyla (ado-trastuzumab emtansine)	BLA 125427	ERBB2 (HER2)	HER-2/neu (ERBB2) gene amplification	P100027/S030	(05/03/2019)	Breast Cancer	ado-trastuzumab emtansine	ERBB2 (HER2)	
InSite Her-2/neu (CB11) Monoclonal Antibody (Biogenex Laboratories, Inc.)	Breast Cancer	Tissue	Herceptin (trastuzumab)	BLA 103792	ERBB2 (HER2)	HER2protein overexpression	P040030	(12/22/2004)	Breast Cancer	trastuzumab	ERBB2 (HER2)	
Ki-67 IHC MIB-1 pharmDx (Dako Omnis) (Agilent Technologies)	Breast Cancer	Tissue	Verzenio (abemaciclib)	NDA 208716	Ki-67	Ki-67 protein expression	P210026	(10/12/2021)	NA	Not in OncoKB	Not in OncoKB	Not in OncoKB
KIT D816V Assay (ARUP Laboratories, Inc.)	Aggressive Systemic Mastocytosis	Bone Marrow	Gleevec (imatinib mesylate)	NDA 021588	KIT	D816V	H140006	(12/18/2015)	NA	We have a different drug here		
LeukoStrat CDx FLT3 Mutation Assay (Invivoscribe Technologies, Inc.)	Acute Myelogenous Leukemia	Peripheral Blood or Bone Marrow	Rydapt (midostaurin)	NDA 207997	FLT3 (ITD/TDK)	ITD mutations and TKD mutations D835 and I836	P160040	(04/28/2017)	Acute Myeloid Leukemia	Midostaurin + High Dose Chemotherapy	FLT3	D835, I836, Internal tandem duplication
LeukoStrat CDx FLT3 Mutation Assay (Invivoscribe Technologies, Inc.)	Acute Myelogenous Leukemia	Peripheral Blood or Bone Marrow	Xospata (gilterinib)	NDA 211349	FLT3 (ITD/TDK)	ITD mutations and TKD mutations D835 and I836	P160040/S002	(11/28/2018)	Acute Myeloid Leukemia	Gilteritinib	FLT3	D835, I836, Internal tandem duplication
MRDx BCR-ABL Test (MolecularMD Corporation)	Chronic Myeloid Leukemia	Peripheral Blood	Tasigna (nilotinib)	NDA 022068	t(9;21) Philadelphia chromosome	BCR-ABL fusion	K173492	(12/22/2017)	Chronic Myelogenous Leukemia	Nilotinib	ABL1	BCR-ABL1 Fusion
Myriad myChoice CDx (Myriad Genetic Laboratories, Inc.)	Ovarian Cancer	Tissue	Lynparza (olaparib)	NDA 208558	Myriad HRD	Deleterious or suspected deleterious mutations in BRCA1 and BRCA2 genes and/or positive Genomic Instability Score)	P190014/S003	(05/08/2020)	Will this get mapped to usual Olaparib indication?			
ONCO/Reveal Dx Lung & Colon Cancer Assay (O/RDx-LCCA) (Pillar Biosciences, Inc.)	Colorectal Cancer	Tissue	Erbitux (cetuximab)	BLA 125084	KRAS	KRAS wild-type (absence of mutations in codons 12 and 13)	P200011	(07/30/2021)	Colorectal Cancer	Cetuximab, Cetuximab + Chemotherapy	KRAS	Wildtype
ONCO/Reveal Dx Lung & Colon Cancer Assay (O/RDx-LCCA) (Pillar Biosciences, Inc.)	Colorectal Cancer	Tissue	Vectibix (panitumumab)	BLA 125147	KRAS	KRAS wild-type (absence of mutations in codons 12 and 13)	P200011	(07/30/2021)	Colorectal Cancer	Panitumumab, Panitumumab + Chemotherapy	KRAS	Wildtype
ONCO/Reveal Dx Lung & Colon Cancer Assay (O/RDx-LCCA) (Pillar Biosciences, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	A tyrosine kinase inhibitor approved by FDA for that indication)		EGFR (HER1)	Exon 19 deletion or exon 21 L858R substitution mutation	P200011	(07/30/2021)	Non-Small Cell Lung Cancer (NSCLC)		EGFR (HER1)	
Oncomine Dx Target Test (Life Technologies Corporation)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Tafinlar (dabrafenib) in combination with Mekinist (trametinib)	NDA 202806 + NDA 204114	BRAF	V600E	P160045	(06/22/2017)	Non-Small Cell Lung Cancer	Dabrafenib + Trametinib	BRAF	V600E
Oncomine Dx Target Test (Life Technologies Corporation)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Xalkori (crizotinib)	NDA 202570	ROS1	ROS1 fusions	P160045	(06/22/2017)	Non-Small Cell Lung Cancer	Crizotinib	ROS1	Fusions
Oncomine Dx Target Test (Life Technologies Corporation)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Iressa (gefitinib)	NDA 206995	EGFR (HER1)	Exon 19 deletion or exon 21 L858R substitution mutation	P160045	(06/22/2017)	Non-Small Cell Lung Cancer	Gefitinib	EGFR	Exon 19 in-frame deletions, L858R
Oncomine Dx Target Test (Life Technologies Corporation)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Gavreto (pralsetinib)	NDA 213721	RET	RET fusions	P160045/S019	(09/04/2020)	Non-Small Cell Lung Cancer	Pralsetinib	RET	Fusions
Oncomine Dx Target Test (Life Technologies Corporation)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Rybrevant (amivantamb)	BLA 761210	EGFR (HER1)	Exon 20 insertion mutations	P160045/S027	(12/01/2021)	Non-Small Cell Lung Cancer	Amivantamab	EGFR	Exon 20 in-frame insertions
Oncomine Dx Target Test (Life Technologies Corporation)	Cholangiocarcinoma	Tissue	Tibsovo (ivosidenib)	NDA 211192	IDH1	Single nucleotide variants	P160045/S028	(08/25/2021)	Intrahepatic Cholangiocarcinoma, Cholangiocarcinoma	Ivosidenib	IDH1	R132
Oncomine Dx Target Test (Life Technologies Corporation)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Exkivity (mobocertinib)	NDA 215310	EGFR (HER1)	Exon 20 insertion mutations	P160045/S029	(09/15/2021)	Non-Small Cell Lung Cancer	Mobocertinib	EGFR	Exon 20 in-frame insertions
Oncomine Dx Target Test (Life Technologies Corporation)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	ENHERTU (fam-trastuzumab deruxtecan-nxki)	BLA 761139	ERBB2	ERBB2 Activating Mutations (SNVs And Exon 20 Insertions)	P160045/S035	(08/11/2022)	Non-Small Cell Lung Cancer (NSCLC)	Trastuzumab Deruxtecan	ERBB2	
Oncomine Dx Target Test (Life Technologies Corporation)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Retevmo (selpercatinib)	NDA 213246	RET	RET fusions	P160045/S031	(09/21/2022)	Non-Small Cell Lung Cancer	Selpercatinib	RET	Fusions
Oncomine Dx Target Test (Life Technologies Corporation)	Medullary Thyroid Cancer (MTC)	Tissue	Retevmo (selpercatinib)	NDA 213246	RET	RET mutations (SNVs, MNVs, and deletions)	P160045/S031	(09/21/2022)	Medullary Thyroid Cancer	Selpercatinib	RET	Oncogenic Mutations
Oncomine Dx Target Test (Life Technologies Corporation)	Thyroid Cancer (TC)	Tissue	Retevmo (selpercatinib)	NDA 213246	RET	RET fusions	P160045/S031	(09/21/2022)	Thyroid Cancer	Selpercatinib	RET	Fusions
PathVysion HER-2 DNA Probe Kit (Abbott Molecular Inc.)	Breast Cancer	Tissue	Herceptin (trastuzumab)	BLA 103792	ERBB2 (HER2)	HER-2/neu (ERBB2) gene amplification	P980024	(12/11/1998)	Breast Cancer	trastuzumab	ERBB2 (HER2)	
PATHWAY anti-Her2/neu (4B5) Rabbit Monoclonal Primary Antibody (Ventana Medical Systems, Inc.)	Breast Cancer	Tissue	Herceptin (trastuzumab)	BLA 103792	ERBB2 (HER2)	HER-2 protein overexpression	P990081	(11/28/2000)	Breast Cancer	trastuzumab	ERBB2 (HER2)	
PATHWAY anti-Her2/neu (4B5) Rabbit Monoclonal Primary Antibody (Ventana Medical Systems, Inc.)	Breast Cancer	Tissue	Kadcyla (ado-trastuzumab emtansine)	BLA 125427	ERBB2 (HER2)	HER-2 protein overexpression	P990081/S039	(05/03/2019)	Breast Cancer	ado-trastuzumab emtansine	ERBB2 (HER2)	
PATHWAY anti-Her2/neu (4B5) Rabbit Monoclonal Primary Antibody (Ventana Medical Systems, Inc.)	Breast Cancer	Tissue	Enhertu (fam-trastuzumab deruxtecan-nxki)	BLA 761139	ERBB2 (HER2)	HER-2 protein overexpression	P990081/S047	(09/30/2022)	Breast Cancer	Trastuzumab Deruxtecan	ERBB2 (HER2)	
PD-L1 IHC 22C3 pharmDx (Dako North America, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Keytruda (pembrolizumab)	BLA 125514	PD-L1	PD-L1 protein expression	P150013	(10/02/2015)	NA	Not in OncoKB	Not in OncoKB	Not in OncoKB
PD-L1 IHC 22C3 pharmDx (Dako North America, Inc.)	Cervical Cancer	Tissue	Keytruda (pembrolizumab)	BLA 125514	PD-L1	PD-L1 protein expression	P150013/S009	(06/12/2018)	NA	Not in OncoKB	Not in OncoKB	Not in OncoKB
PD-L1 IHC 22C3 pharmDx (Dako North America, Inc.)	Head and Neck Squamous Cell Carcinoma (HNSCC)	Tissue	Keytruda (pembrolizumab)	BLA 125514	PD-L1	PD-L1 protein expression	P150013/S014	(06/10/2019)	NA	Not in OncoKB	Not in OncoKB	Not in OncoKB
PD-L1 IHC 22C3 pharmDx (Dako North America, Inc.)	Esophageal Squamous Cell Carcinoma (ESCC)	Tissue	Keytruda (pembrolizumab)	BLA 125514	PD-L1	PD-L1 protein expression	P150013/S016	(07/30/2019)	NA	Not in OncoKB	Not in OncoKB	Not in OncoKB
PD-L1 IHC 22C3 pharmDx (Dako North America, Inc.)	Tripl- Negative Breast Cancer (TNBC)	Tissue	Keytruda (pembrolizumab)	BLA 125514	PD-L1	PD-L1 protein expression	P150013/S020	(11/13/2020)	NA	Not in OncoKB	Not in OncoKB	Not in OncoKB
PD-L1 IHC 22C3 pharmDx (Dako North America, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Libtayo (cemiplimab-rwlc)	BLA 761097	PD-L1	PD-L1 protein expression [Tumor Proportion Score (TPS) ≥ 50%]	P150013/S021	(02/22/2021)	NA	Not in OncoKB	Not in OncoKB	Not in OncoKB
PD-L1 IHC 28-8 pharmDx (Dako North America, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Opdivo (nivolumab) in combination with Yervoy (ipilimumab)	BLA 125554 + BLA 125377	PD-L1	PD-L1 protein expression (tumor cell staining ≥1%)	P150025/S013	(05/15/2020)	NA	Not in OncoKB	Not in OncoKB	Not in OncoKB
PDGFRB FISH Assay (ARUP Laboratories, Inc.)	Myelodysplastic Syndrome/Myeloproliferative Disease	Bone Marrow	Gleevec (imatinib mesylate)	NDA 021588	PDGFRB	PDGFRB gene rearrangement at 5q31~33	H140005	(12/18/2015)	Myelodysplastic/Myeloproliferative Neoplasms	Imatinib	PDGFRB	Fusions
Praxis Extended RAS Panel (Illumina, Inc.)	Colorectal cancer	Tissue	Vectibix (panitumumab)	BLA 125147	KRAS and NRAS	KRAS wild-type (absence of mutations in exons 2, 3, and 4) and NRAS wild type (absence of mutations in exons 2, 3, and 4)	P160038	(06/29/2017)	Colorectal Cancer	Panitumumab, Panitumumab + Chemotherapy	KRAS, NRAS	Wildtype
SeCore CDx HLA Sequencing System (One Lambda Inc.	Uveal Melanoma	Whole Blood	Kimmtrak (tebentafusp-tebn)	BLA 761228	HLA	HLA-A*02:01	BR220737	(11/28/2022)	NA	Not in OncoKB	Not in OncoKB	Not in OncoKB
SPOT-LIGHT HER2 CISH Kit (Life Technologies Corporation)	Breast Cancer	Tissue	Herceptin (trastuzumab)	BLA 103792	ERBB2 (HER2)	HER-2/neu (ERBB2) gene amplification	P050040	(07/01/2008)	Breast Cancer	trastuzumab	ERBB2 (HER2)	
therascreen BRAF V600E RGQ PCR Kit (QIAGEN GmbH)	Colorectal Cancer	Tissue	Braftovi (encorafenib)NDA 210496 in combination with Erbitux (cetuximab)	NDA 210496 + BLA 125084	BRAF	V600E	P190026	(04/15/2020)	Colorectal Cancer	Encorafenib + Cetuximab	BRAF	V600E
therascreen EGFR RGQ PCR Kit (Qiagen Manchester, Ltd.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Gilotrif (afatinib)	NDA 201292	EGFR (HER1)	Exon 19 deletion or exon 21 L858R substitution mutation	P120022	(07/12/2013)	Non-Small Cell Lung Cancer	Afatinib	EGFR	Exon 19 in-frame deletions, L858R
therascreen EGFR RGQ PCR Kit (Qiagen Manchester, Ltd.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Iressa (gefitinib)	NDA 206995	EGFR (HER1)	Exon 19 deletion or exon 21 L858R substitution mutation	P120022/S001	(07/10/2015)	Non-Small Cell Lung Cancer	Gefitinib	EGFR	Exon 19 in-frame deletions, L858R
therascreen EGFR RGQ PCR Kit (Qiagen Manchester, Ltd.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Gilotrif (afatinib)	NDA 201292	EGFR (HER1)	L861Q, G719X and S7681	P120022/S016	(01/12/2016)	Non-Small Cell Lung Cancer	Afatinib	EGFR	G719, L861Q, S768I
therascreen EGFR RGQ PCR Kit (Qiagen Manchester, Ltd.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Vizimpro (dacomitinib)	NDA 211288	EGFR (HER1)	Exon 19 deletion or exon 21 L858R substitution mutation	P120022/S018	(09/27/2018)	Non-Small Cell Lung Cancer	Dacomitinib	EGFR	Exon 19 in-frame deletions, L858R
therascreen FGFR RGQ RT-PCR Kit (QIAGEN Manchester Ltd.)	Urothelial Cancer	Tissue	Balversa (erdafitinib)	NDA 212018	FGFR3	Exon 7: R248C (c.742C>T), S249C (c.746C>G); exon 10: G370C (c.1108G>T) and Y373C (c.1118A>G); and fusions (FGFR3-TACC3v1 and FGFR3-TACC3v3)	P180043	(04/12/2019)	Bladder Cancer	Erdafitinib	FGFR3	G370C, R248C, S249C, Y373C, Fusions
therascreen KRAS RGQ PCR Kit (Qiagen Manchester, Ltd.)	Colorectal Cancer	Tissue	Vectibix (panitumumab)	BLA 125147	KRAS	G12A, G12D, G12R, G12C, G12S, G12V, G13D	P110027	(05/23/2014)	NA	Not in OncoKB	Not in OncoKB	Not in OncoKB
therascreen KRAS RGQ PCR Kit (Qiagen Manchester, Ltd.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Lumakras (sotorasib)	NDA 214665	KRAS	G12C	P110027/S012	(05/28/2021)	Non-Small Cell Lung Cancer	Sotorasib	KRAS	G12C
therascreen KRAS RGQ PCR Kit (Qiagen Manchester, Ltd.)	Colorectal Cancer	Tissue	Erbitux (cetuximab)	BLA 125084	KRAS	G12A, G12D, G12R, G12C, G12S, G12V, G13D	P110030	(07/06/2012)	NA	Not in OncoKB	Not in OncoKB	Not in OncoKB
therascreen KRAS RGQ PCR Kit (Qiagen Manchester, Ltd.)	Colorectal Cancer	Tissue	Erbitux (cetuximab)	BLA 125084	KRAS	KRAS wild-type (absence of mutations in codons 12 and 13)	P110027/S013	(12/02/2022)	Colorectal Cancer	Cetuximab, Cetuximab + Chemotherapy	KRAS	Wildtype
therascreen KRAS RGQ PCR Kit (Qiagen Manchester, Ltd.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Krazati (adagrasib)	NDA 216340	KRAS	KRAS G12C	P110027/S013	(12/02/2022)	Non-Small Cell Lung Cancer	Adagrasib	KRAS	G12C
therascreen PIK3CA RGQ PCR Kit (QIAGEN GmbH)	Breast Cancer	Tissue or Plasma	Piqray (alpelisib)	NDA 212526	PIK3CA	C420R, E542K, E545A, E545D [1635G>T only], E545G, E545K, Q546E, Q546R, H1047L, H1047R, and H1047Y	P190001 and P190004	(05/24/2019) and (05/24/2019)	Breast Cancer	Alpelisib + Fulvestrant	PIK3CA	C420R, E542K, E545A, E545D, E545G, E545K, H1047L, H1047R, H1047Y, Q546E, Q546R
THXID BRAF Kit (bioMérieux Inc.)	Melanoma	Tissue	Mekinist (trametinib)	NDA 204114	BRAF	V600E or V600K	P120014	(05/29/2013)	Melanoma	Trametinib	BRAF	V600E, V600K
THXID BRAF Kit (bioMérieux Inc.)	Melanoma	Tissue	Tafinlar (dabrafenib)	NDA 202806	BRAF	V600E	P120014	(05/29/2013)	Melanoma	Dabrafenib	BRAF	V600E
THXID BRAF Kit (bioMérieux Inc.)	Melanoma	Tissue	Braftovi (encorafenib) in combination with Mektovi (binimetinib)	NDA 210496 + NDA 210498	BRAF	V600E or V600K	P120014/S008	(06/27/2018)	Melanoma	Encorafenib + Binimetinib	BRAF	V600E, V600K
Ventana ALK (D5F3) CDx Assay (Ventana Medical Systems, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Xalkori (crizotinib)	NDA 202570	ALK	ALK protein expression	P140025	(06/12/2015)	NA	Not in OncoKB	Not in OncoKB	Not in OncoKB
Ventana ALK (D5F3) CDx Assay (Ventana Medical Systems, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Zykadia (ceritinib)	NDA 211225	ALK	ALK protein expression	P140025/S005	(05/26/2017)	NA	Not in OncoKB	Not in OncoKB	Not in OncoKB
Ventana ALK (D5F3) CDx Assay (Ventana Medical Systems, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Alecensa (alectinib)	NDA 208434	ALK	ALK protein expression	P140025/S006	(11/06/2017)	NA	Not in OncoKB	Not in OncoKB	Not in OncoKB
Ventana ALK (D5F3) CDx Assay (Ventana Medical Systems, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Lorbrena (lorlatinib)	NDA 210868	ALK	ALK protein expression	P140025/S014	(03/03/2021)	NA	Not in OncoKB	Not in OncoKB	Not in OncoKB
Ventana FOLR1 (FOLR-2.1) RxDx Assay (Ventana Medical Systems, Inc.)	Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	Tissue	Elahere (mirvetuximab soravtansine-gynx)	BLA 761310	FOLR1	FOLR1 protein expression	P220006	(11/14/2022)	NA	Not in OncoKB	Not in OncoKB	Not in OncoKB
Ventana HER2 Dual ISH DNA Probe Cocktail (Ventana Medical Systems, Inc.)	Breast Cancer	Tissue	Herceptin (trastuzumab)	BLA 103792	ERBB2 (HER2)	HER-2/neu (ERBB2) gene amplification	P190031	(07/28/2020)	Breast Cancer	trastuzumab	ERBB2 (HER2)	
Ventana MMR RxDx Panel (Ventana Medical Systems, Inc.)	Endometrial Carcinoma (EC)	Tissue	Jemperli (dostarlimag-gxly)	NDA 761174	deficient mismatch repair (dMMR) proteins	MLH1, PMS2, MSH2 and MSH6	P200019	(04/22/2021)	NA	Not in OncoKB	Not in OncoKB	Not in OncoKB
Ventana MMR RxDx Panel (Ventana Medical Systems, Inc.)	Solid Tumors		Jemperli (dostarlimag-gxly)	NDA 761174	deficient mismatch repair (dMMR) proteins	MLH1, PMS2, MSH2 and MSH6	P210001	(08/17/2021)	NA	Not in OncoKB	Not in OncoKB	Not in OncoKB
Ventana MMR RxDx Panel (Ventana Medical Systems, Inc.)	Solid Tumors		Keytruda (pembrolizumab)	BLA 125514	deficient mismatch repair (dMMR) proteins	MLH1, PMS2, MSH2 and MSH6	P210001/S001	(03/21/2022)	NA	Not in OncoKB	Not in OncoKB	Not in OncoKB
Ventana MMR RxDx Panel (Ventana Medical Systems, Inc.)	Endometrial Carcinoma (EC)	Tissue	Keytruda (pembrolizumab) in combination with Lenvima (lenvatinib) )	BLA 125514 + NDA 206947	proficient mismatch repair (pMMR) proteins	MLH1, PMS2, MSH2 and MSH6	P210001/S002	(06/16/2022)	NA	Not in OncoKB	Not in OncoKB	Not in OncoKB
Ventana PD-L1 (SP142) Assay (Ventana Medical Systems, Inc.)	Urothelial Carcinoma	Tissue	Tecentriq (atezolizumab)	BLA 761034	PD-L1	PD-L1 protein expression (PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 5% of the tumor area)	P160002	(05/18/2016)	NA	Not in OncoKB	Not in OncoKB	Not in OncoKB
Ventana PD-L1 (SP142) Assay (Ventana Medical Systems, Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Tecentriq (atezolizumab)	BLA 761034	PD-L1	PD-L1 protein expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%])	P160002/S006	(07/02/2018)	NA	Not in OncoKB	Not in OncoKB	Not in OncoKB
Ventana PD-LI (SP263) Assay (Ventana Medical Systems, Inc)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Tecentriq (atezolizumab)	BLA 761034	PD-L1	PD-L1 protein expression	P160046/S010	(10/15/2021)	NA	Not in OncoKB	Not in OncoKB	Not in OncoKB
Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Xalkori (crizotinib)	NDA 202570	ALK	ALK gene rearrangements	P110012	(08/26/2011)	Non-Small Cell Lung Cancer	Crizotinib	ALK	Fusions
Vysis ALK Break Apart FISH Probe Kit (Abbott Molecular Inc.)	Non-Small Cell Lung Cancer (NSCLC)	Tissue	Alunbrig (brigatinib)	NDA 208772	ALK	ALK gene rearrangements	P110012/S020	(05/22/2020)	Non-Small Cell Lung Cancer	Brigatinib	ALK	Fusions
Vysis CLL FISH Probe Kit (Abbott Molecular, Inc.)	B-cell Chronic Lymphocytic Leukemia	Peripheral Blood	Venclexta (venetoclax)	NDA 208573	TP53	Deletion chromosome 17p (17p-)	P150041	(04/11/2016)	Colorectal Cancer	Cetuximab, Cetuximab + Chemotherapy	KRAS	Wildtype
xT CDx (Tempus Labs, Inc.)	Colorectal Cancer (CRC)	Tissue (Matching Blood/Saliva)	Erbitux (cetuximab)	BLA 125084	KRAS	KRAS wild-type (absence of mutations in codons 12 or 13)	P210011	(04/28/2023)				
xT CDx (Tempus Labs, Inc.)	Colorectal Cancer (CRC)	Tissue (Matching Blood/Saliva)	Vectibix (panitumumab)	BLA 125147	KRAS and NRAS	KRAS wild-type (absence of mutations in exons 2, 3, or 4) and NRAS wild-type (absence of mutations in exons 2, 3, or 4)	P210011	(04/28/2023)	Colorectal Cancer	Panitumumab, Panitumumab + Chemotherapy	KRAS, NRAS	Wildtype